Drug-Coated Balloons for De Novo Coronary Artery Lesions: A Meta-Analysis of Randomized Clinical Trials
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Through meta-analysis, we aimed to assess the efficacy and safety of drug-coated balloons (DCB), compared with drug eluting stents (DES) or uncoated devices, in the treatment of de novo coronary lesions. Materials and Methods: Only randomized controlled trials were included. The primary outcomes were late lumen loss (LLL), target lesion revascularization (TLR), and major adverse cardiac events (MACEs). Subgroup analyses were conducted based on clinical indications, whether DCBs were used with a systematic or bailout stent, and types of DESs. Results: The present meta-analysis demonstrated that DCBs elicit significantly lower incidences of TLR, MACE, and LLL, com pared with uncoated devices, and similar incidences, compared with DESs, in the treatment of de novo coronary lesions. Subgroup analysis indicated that DCBs used with a bailout stent achieved lower incidences of binary restenosis and myocardial infarction, compared with uncoated devices, and provided less LLL than DESs. DCBs showed similar rates of TLR and MACE, with signifi cantly less LLL, than DESs in treating de novo small-vessel diseases. The clinical efficacy of DCBs was similar to that of second generation DES. Conclusion: Overall, DCB is favored over bare metal stent alone in treating de novo coronary lesions. DCBs appear to be a prom ising alternative to DESs in the treatment of de novo coronary lesions.
Abstract
Purpose: Through meta-analysis, we aimed to assess the efficacy and safety of drug-coated balloons (DCB), compared with drug eluting stents (DES) or uncoated devices, in the treatment of de novo coronary lesions. Materials and Methods: Only randomized controlled trials were included. The primary outcomes were late lumen loss (LLL), target lesion revascularization (TLR), and major adverse cardiac events (MACEs). Subgroup analyses were conducted based on clinical indications, whether DCBs were used with a systematic or bailout stent, and types of DESs. Results: The present meta-analysis demonstrated that DCBs elicit significantly lower incidences of TLR, MACE, and LLL, com pared with uncoated devices, and similar incidences, compared with DESs, in the treatment of de novo coronary lesions. Subgroup analysis indicated that DCBs used with a bailout stent achieved lower incidences of binary restenosis and myocardial infarction, compared with uncoated devices, and provided less LLL than DESs. DCBs showed similar rates of TLR and MACE, with signifi cantly less LLL, than DESs in treating de novo small-vessel diseases. The clinical efficacy of DCBs was similar to that of second generation DES. Conclusion: Overall, DCB is favored over bare metal stent alone in treating de novo coronary lesions. DCBs appear to be a prom ising alternative to DESs in the treatment of de novo coronary lesions.
참고문헌 (41)
- Khan MA, "Global epidemiology of ischemic heart disease : results from the global burden of disease study", Cureus, 12, pp.e9349~ (2020)
- Otsuka F, "Pathology of second-generation everolimus-eluting stents versus first-generation sirolimus-and paclitaxel-eluting stents in humans", Circulation, 129, pp.211~223 (2014)
- Hassan AK, "Late stent malapposition risk is higher after drugeluting stent compared with bare-metal stent implantation and associates with late stent thrombosis", Eur Heart J, 31, pp.1172~1180 (2010)
- Alfonso F, "State of the art : balloon catheter technologies-drug-coated balloon", EuroIntervention, 13, pp.680~695 (2017)
- Cortese B, "Treatment of bifurcation lesions with drug-coated balloons : a review of currently available scientific data", Int J Cardiol, 220, pp.589~594 (2016)
- Schulz A, "Treatment of coronary de novo bifurcation lesions with DCB only strategy", Clin Res Cardiol, 103, pp.451~456 (2014)
- Waksman R, "Drug-coated balloons for de novo coronary lesions : results from the Valentines II trial", EuroIntervention, 9, pp.613~619 (2013)
- Cortese B, "Paclitaxel coated balloons for coronary artery interventions : a comprehensive review of preclinical and clinical data", Int J Cardiol, 161, pp.4~12 (2012)
- Elgendy IY, "Meta-analysis comparing the frequency of target lesion revascularization with drug-coated balloons or second-generation drug-eluting stents for coronary in-stent restenosis", Am J Cardiol, 123, pp.1186~1187 (2019)
- Byrne RA, "Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drugeluting stent(ISAR-DESIRE 3) : a randomised, open-label trial", Lancet, 381, pp.461~467 (2013)
- Giacoppo D, "Paclitaxel-coated balloon angioplasty vs. drug-eluting stenting for the treatment of coronary in-stent restenosis : a comprehensive, collaborative, individual patient data meta-analysis of 10 randomized clinical trials(DAEDALUS study)", Eur Heart J, 41, pp.3715~3728 (2020)
- Neumann FJ, "2018 ESC", EACTS guidelines on myocardial revascularization, 2019, pp.40, 87~165
- Besic KM, "Drug-eluting balloons in patients with non-ST elevation acute coronary syndrome", J Cardiol, 65, pp.203~207 (2015)
- Cortese B, "Drug-coated balloon versus drug-eluting stent for small coronary vessel disease : PICCOLETO II randomized clinical trial", JACC Cardiovasc Interv, 13, pp.2840~2849 (2020)
- García-Touchard A, "A randomised trial of paclitaxel-eluting balloon after bare metal stent implantation vs. bare metal stent in STelevation myocardial infarction(the PEBSI study)", EuroIntervention, 12, pp.1587~1594 (2017)
- Jing QM, "A drugeluting Balloon for the trEatment of coronarY bifurcatiON lesions in the side branch: a prospective multicenter ranDomized (BEYOND)clinical trial in China", Chin Med J(Engl), 133, pp.899~908 (2020)
- 채인호, "Comparison of Drug-Eluting Balloon Followed by Bare Metal Stent with Drug-Eluting Stent for Treatment of de Novo Lesions: Randomized, Controlled, Single-Center Clinical Trial", Journal of Korean Medical Science, 32(6), pp.933~941 (2017), 대한의학회
- Jeger RV, "Drug-coated balloons for small coronary artery disease(BASKET-SMALL 2) : an open-label randomised non-inferiority trial", Lancet, 392, pp.849~856 (2018)
- Latib A, "A randomized multicenter study comparing a paclitaxel drugeluting balloon with a paclitaxel-eluting stent in small coronary vessels : the BELLO(balloon elution and late loss optimization)study", J Am Coll Cardiol, 60, pp.2473~2480 (2012)
- Belkacemi A, "First results of the DEB-AMI(drug eluting balloon in acute ST-segment elevation myocardial infarction)trial : a multicenter randomized comparison of drug-eluting balloon plus bare-metal stent versus bare-metal stent versus drug-eluting stent in primary percutaneous coronary intervention with 6-month angiographic, intravascular, functional, and clinical outcomes", J Am Coll Cardiol, 59, pp.2327~2337 (2012)
- López Mínguez JR, "A prospective randomised study of the paclitaxel-coated balloon catheter in bifurcated coronary lesions(BABILON trial) : 24-month clinical and angiographic results", EuroIntervention, 10, pp.50~57 (2014)
- Stella PR, "A multicenter randomized comparison of drug-eluting balloon plus bare-metal stent versus bare-metal stent versus drug-eluting stent in bifurcation lesions treated with a single-stenting technique : six-month angiographic and 12-month clinical results of the drugeluting balloon in bifurcations trial", Catheter Cardiovasc Interv, 80, pp.1138~1146 (2012)
- Bhandari M, "Quality in the reporting of randomized trials in surgery : is the Jadad scale reliable?", Control Clin Trials, 22, pp.687~688 (2001)
- Higgins JP, "Measuring inconsistency in meta-analyses", BMJ, 327, pp.557~560 (2003)
- Liu W, "Drug-coated balloon for de novo coronary artery lesions : a systematic review and trial sequential meta-analysis of randomized controlled trials", Cardiovasc Ther, 2020, pp.4158363~ (2020)
- Elgendy IY, "Clinical and angiographic outcomes with drug-coated balloons for de novo coronary lesions : a meta-analysis of randomized clinical trials", J Am Heart Assoc, 9, pp.e016224~ (2020)
- Megaly M, "Outcomes with drug-coated balloons vs. drug-eluting stents in small-vessel coronary artery disease", Cardiovasc Revasc Med, 35, pp.76~82 (2022)
- Megaly M, "Outcomes with drug-coated balloons for treating the side branch of coronary bifurcation lesions", J Invasive Cardiol, 30, pp.393~399 (2018)
- Li M, "Drug-coated balloon versus drug-eluting stent in de novo small coronary vessel disease : a systematic review and meta-analysis", Medicine(Baltimore), 98, pp.e15622~ (2019)
- Palmerini T, "Long-term safety of drug-eluting and bare-metal stents : evidence from a comprehensive network metaanalysis", J Am Coll Cardiol, 65, pp.2496~2507 (2015)
- Kheiri B, "Drug-eluting stents versus baremetal stents with a single month of dual antiplatelet therapy : a trial sequential analysis", J Thromb Thrombolysis, 48, pp.11~13 (2019)
- Shin ES, "Prospective randomized trial of paclitaxel-coated balloon versus baremetal stent in high bleeding risk patients with de novo coronary artery lesions", Coron Artery Dis, 30, pp.425~431 (2019)
- Rissanen TT, "Drug-coated balloon for treatment of de-novo coronary artery lesions in patients with high bleeding risk(DEBUT) : a singleblind, randomised, non-inferiority trial", Lancet, 394, pp.230~239 (2019)
- Machecourt J, "Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients : the EVASTENT matched-cohort registry", J Am Coll Cardiol, 50, pp.501~508 (2007)
- Joner M, "Pathology of drug-eluting stents in humans : delayed healing and late thrombotic risk", J Am Coll Cardiol, 48, pp.193~202 (2006)
- Katsanos K, "Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg : a systematic review and meta-analysis of randomized controlled trials", J Am Heart Assoc, 7, pp.e011245~ (2018)
- Unverdorben M, "Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis : the three-year results of the PEPCAD II ISR study", EuroIntervention, 11, pp.926~934 (2015)
- Burzotta F, "Impact of drug-eluting balloon(pre-or post-)dilation on neointima formation in de novo lesions treated by bare-metal stent : the IN-PACT CORO trial", Heart Vessels, 31, pp.677~686 (2016)
- Cassese S, "Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents : a meta-analysis of randomised controlled trials", Lancet, 387, pp.537~544 (2016)
- Gada H, "5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents : final results from the SPIRIT III trial(clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions)", JACC Cardiovasc Interv, 6, pp.1263~1266 (2013)
- Shiomi H, "Long-term clinical outcomes after everolimus-and sirolimuseluting coronary stent implantation : final 3-year follow-up of the randomized evaluation of sirolimus-eluting versus everolimus-eluting stent trial", Circ Cardiovasc Interv, 7, pp.343~354 (2014)